# Dr Reddy’s terminates distribution pact with Novartis India 2026-08-10T18:50:59+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 1 independent outlet Drugmaker Dr Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India, citing a change in the Swiss firm's controlling shareholding. The pact, signed in February 2022, will end by September 30, 2026, Dr Reddy's said in a stock exchange filing on August 10. Novartis India confirmed the termination agreement was executed on August 7 and will regain exclusivity and market access for the affected products. The termination follows private equity firm ChrysCapital's acquisition of a controlling 70.68% stake in Novartis India, announced on July 29. This is ChrysCapital's first majority-controlled investment in Indian pharma. Novartis India's key brands include painkiller Voveran, calcium supplement Calcium Sandoz, and anti-epilepsy drug Tegrital, covering areas like gynaecology and transplant immunology. ## Coverage - thehindu.com Tags: ChrysCapital, Distribution pact termination, Dr Reddy's Laboratories, Novartis India, Pharmaceutical M&A, Stock exchange filing Canonical: https://indianopinion.org/dr-reddys-terminates-distribution-pact-with-novartis-india/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/dr-reddys-terminates-distribution-pact-with-novartis-india/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.